Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects
- 1 July 2018
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 40 (7) , 1108-1121.e8
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal studyParkinsonism & Related Disorders, 2017
- Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal studyParkinsonism & Related Disorders, 2016
- The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s diseaseTranslational Neurodegeneration, 2016
- Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropiniroleMovement Disorders, 2007
- Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trialThe Lancet Neurology, 2007
- Advanced Parkinson disease treated with rotigotine transdermal systemNeurology, 2007
- Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030Neurology, 2007
- Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson diseaseNeurology, 2007
- A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's DiseaseArchives of Neurology, 2003
- Pharmacokinetics of the Dopamine D2 Agonist S(-)-2-(M-Propyl-M-2-thienylethylamino)-5-hydroxytetralin in Freely Moving RatsJournal of Pharmaceutical Sciences, 1993